Regimen Wealth LLC Buys Shares of 1,232 Johnson & Johnson (NYSE:JNJ)

Posted by on May 6th, 2023

Regimen Wealth LLC bought a new stake in shares of Johnson & Johnson (NYSE:JNJ – Get Rating) in the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor bought 1,232 shares of the company’s stock, valued at approximately $218,000.

Other hedge funds and other institutional investors have also added to or reduced their stakes in the company. Glassy Mountain Advisors Inc. bought a new position in shares of Johnson & Johnson in the fourth quarter worth approximately $35,000. Retirement Financial Solutions LLC bought a new position in shares of Johnson & Johnson during the fourth quarter worth $40,000. TD Capital Management LLC purchased a new position in Johnson & Johnson during the third quarter valued at $48,000. VitalStone Financial LLC bought a new stake in Johnson & Johnson in the 4th quarter valued at $52,000. Finally, Iron Horse Wealth Management LLC lifted its stake in Johnson & Johnson by 112.8% in the 4th quarter. Iron Horse Wealth Management LLC now owns 300 shares of the company’s stock worth $53,000 after purchasing an additional 159 shares in the last quarter. 67.94% of the stock is owned by hedge funds and other institutional investors.

Insiders Place Their Bets

In other Johnson & Johnson news, insider James D. Swanson sold 1,062 shares of the company’s stock in a transaction on Monday, March 6th. The stock was sold at an average price of $154.66, for a total value of $164,248.92. Following the completion of the sale, the insider now directly owns 9,215 shares in the company, valued at approximately $1,425,191.90. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. 0.20% of the stock is currently owned by company insiders.

Analyst Ratings Changes

Several brokerages have recently issued reports on JNJ. Guggenheim assumed coverage on Johnson & Johnson in a report on Tuesday, February 28th. They issued a “neutral” rating and a $161.00 target price on the stock. SVB Leerink decreased their price objective on Johnson & Johnson from $194.00 to $186.00 and set an “outperform” rating on the stock in a report on Friday, January 20th. Morgan Stanley upped their price target on shares of Johnson & Johnson from $179.00 to $183.00 and gave the company an “equal weight” rating in a research note on Wednesday, April 19th. Raymond James dropped their price objective on shares of Johnson & Johnson from $185.00 to $181.00 and set an “outperform” rating for the company in a research note on Wednesday, April 19th. Finally, Credit Suisse Group upped their target price on shares of Johnson & Johnson from $168.00 to $170.00 in a research report on Friday. Seven analysts have rated the stock with a hold rating, six have issued a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat, Johnson & Johnson presently has a consensus rating of “Moderate Buy” and an average price target of $173.00.

Johnson & Johnson Stock Up 0.3 %

Shares of NYSE:JNJ opened at $162.68 on Friday. The business has a 50 day simple moving average of $158.33 and a two-hundred day simple moving average of $166.96. Johnson & Johnson has a 1 year low of $150.11 and a 1 year high of $183.35. The company has a debt-to-equity ratio of 0.49, a current ratio of 1.07 and a quick ratio of 0.77. The firm has a market capitalization of $422.76 billion, a PE ratio of 34.03, a price-to-earnings-growth ratio of 2.78 and a beta of 0.53.

Johnson & Johnson (NYSE:JNJ – Get Rating) last announced its quarterly earnings data on Tuesday, April 18th. The company reported $2.68 earnings per share for the quarter, beating analysts’ consensus estimates of $2.51 by $0.17. The company had revenue of $24.75 billion during the quarter, compared to analyst estimates of $23.61 billion. Johnson & Johnson had a net margin of 13.22% and a return on equity of 36.13%. The firm’s revenue for the quarter was up 5.6% on a year-over-year basis. During the same quarter last year, the business posted $2.67 EPS. On average, equities analysts predict that Johnson & Johnson will post 10.66 EPS for the current year.

Johnson & Johnson Increases Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, June 6th. Investors of record on Tuesday, May 23rd will be paid a $1.19 dividend. The ex-dividend date of this dividend is Monday, May 22nd. This represents a $4.76 annualized dividend and a yield of 2.93%. This is a boost from Johnson & Johnson’s previous quarterly dividend of $1.13. Johnson & Johnson’s dividend payout ratio is 94.56%.

About Johnson & Johnson

(Get Rating)

Johnson & Johnson is a holding company, which engages in the research and development, manufacture and sale of products in the health care field. It operates through the following segments: Consumer Health, Pharmaceutical, and MedTech. The Consumer Health segment includes products focused on personal healthcare used in the Skin Health/Beauty, Over-the-Counter medicines, Baby Care, Oral Care, Women’s Health and Wound Care markets.

Featured Articles

Institutional Ownership by Quarter for Johnson & Johnson (NYSE:JNJ)

Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.